Beyfortus® (nirsevimab-alip)
for Respiratory Syncytial Virus

Beyfortus (nirsevimab-alip) is used to protect babies under 1 year of age from serious RSV lung infections and may also be given to children up to 2 years old at risk of severe RSV disease through their second RSV season. It contains nirsevimab-alip, a long-acting monoclonal antibody that targets the RSV F protein, preventing the virus from entering cells and multiplying. Beyfortus provides passive protection during the RSV season to reduce the risk of severe lower respiratory infections caused by RSV.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Respiratory Syncytial Virus - RSV

No other medications found.